

Antibody-Drug Conjugates: Pharmacist Focus on Overcoming the Challenges of Adverse Event Management

PODCAST

KEY REFERENCES

1. Tong JTW, Harris PWR, Brimble MA, Kavianinia I. An insight into FDA approved antibody-drug conjugates for cancer therapy. *Molecules*. 2021;26(19):5847. doi:10.3390/molecules26195847
2. Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. *Lancet*. 2019;394(10200):793-804. doi:10.1016/S0140-6736(19)31774-X
3. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. *Nat Rev Clin Oncol*. 2021;18(6):327-344. doi:10.1038/s41571-021-00470-8
4. Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. *Molecules*. 2020;25(20):4764. doi:10.3390/molecules25204764
5. Marmé F. Antibody-drug conjugates for breast cancer. *Oncol Res Treat*. 2022;45(1-2):26-36. doi:10.1159/000521499
6. Ladha A, Mannis G, Muffly L. Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin. *Leuk Lymphoma*. 2021;62(2):257-263. doi:10.1080/10428194.2020.1827247
7. Lievano FA, Scarazzini LJ, Tyczynski JE, et al. Risk minimization of antibody-drug conjugates in oncology: a review. *Drug Saf*. 2021;44(7):733-742. doi:10.1007/s40264-021-01069-9
8. Wahab A, Rafae A, Mushtaq K, et al. Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. *Front Oncol*. 2021 May 11;11:678634. doi:10.3389/fonc.2021.678634
9. Atiq S, Hirshman N, Shariff A, Zhang T. The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer [published online ahead of print December 30, 2021]. *Urol Oncol*. 2021 Dec 30;S1078-1439(21)00471-3. doi:10.1016/j.urolonc.2021.10.002
10. Spring LM, Nakajima E, Hutchinson J, et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities. *Oncologist*. 2021;26(10):827-834. doi:10.1002/onco.13878

RESOURCES FOR PATIENTS AND PROVIDERS

<p>ADC Review <i>Resource for clinicians on the use of commercially available antibody-drug conjugates approved by the FDA</i></p>	<p>https://www.adcreview.com/resources-for-for-clinicians/</p>
<p>ASCO Educational Book <i>Antibody-drug conjugates: patient and treatment selection</i></p>	<p>https://ascopubs.org/doi/10.1200/EDBK_280775</p>